Your session is about to expire
← Back to Search
Tolerogenic Dendritic Cell Vaccine for Type 1 Diabetes
Study Summary
This trial is testing a vaccine to see if it can stop the body from attacking itself in people with type 1 diabetes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My organs are functioning well.I do not have diabetes-related complications like kidney, eye, or nerve damage.I have a history of HIV, hepatitis B, hepatitis C, HTLV, or syphilis.I am eligible for a procedure to collect my own cells.I am not on any prescription anti-inflammatory drugs, but I may use OTC like ibuprofen or Tylenol.Your C-peptide level is higher than 0.017 nmol/L even when you haven't fasted.I do not have the HLA-DRB1*15:01 genetic marker.I haven't taken diabetes medication that stimulates insulin production in the last 2 months.I have Type 1 diabetes or no symptoms from autoimmune conditions.I have or had cancer before.I was diagnosed between 1 and 4 years ago.I have been taking medication to lower my blood sugar for at least 2 months.I have had a blood clot or stroke in the past.My heart condition is stable.Your C-peptide levels are higher than 0.2 nmol/L after a 2-hour test.I have not received any vaccines in the last 28 days.I have antibodies linked to type-1 diabetes.I haven't had allergy shots in the last 28 days.You are not taking any other experimental drugs or biologic treatments.Your HbA1c level should be less than or equal to 7.5%.Your blood sugar levels are well-managed according to your doctor.You have had an organ transplant from someone else in the past.I am receiving or have received monoclonal antibody therapy.I have the *04:01, *04:02, or *04:04 allele in my HLA-DRB1 gene.I have a serious illness that is not under control.I am not pregnant or breastfeeding.I am not on any strong immune system suppressing drugs.You have had a positive PPD skin test in the past.I haven't taken any corticosteroids in the last 28 days.I am willing to undergo a procedure to collect white blood cells.I am currently taking medication for an infection.Only for those who have never used a continuous glucose monitoring device before: You are able to use the device correctly after being trained by a certified diabetes educator and the device manufacturer.You have a history of needing strong medicine for allergies or having severe allergic reactions.I have been diagnosed with type 1 diabetes.
- Group 1: Autologous Tolerogenic Dendritic Cell with Proinsulin Peptide (PIpepTolDC)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What core aims are this trial endeavoring to achieve?
"The primary intention of this long-term study is to measure Apheresis duration over the course of two years. Secondary objectives include evaluating alteration in immune phenotype, gauging changes in glycosylated hemoglobin A1c (HbA1c) levels, and investigating any modifications to T cell responsiveness via Lymphocyte Stimulation Test(LST)."
Am I qualified to take part in this research endeavor?
"To access the trial, individuals must have a diagnosis of diabetes mellitus and be within the age group of 18 to 45 years old. At this point in time, approximately 7 candidates are needed for enrolment into the initiative."
Are there any vacant slots open for prospective participants of this experiment?
"As evidenced by the information found on clinicaltrials.gov, the investigators are still looking for qualified participants. This trial was first advertised on June 16th 2022 and recently updated July 26th 2022."
Is there an age restriction for individuals wishing to participate in this experiment?
"Eligible patients for this trial must be over 18 years old and not exceed 45 years of age."
Has the FDA sanctioned Tolerogenic Dendritic Cell Vaccine?
"Tolerogenic Dendritic Cell Vaccine's safety has been assessed as a 1 due to its Phase 1 status, indicating that there is limited evidence of efficacy and safety."
What is the capacity of this research trial in terms of participants?
"Correct. According to clinicaltrials.gov, this trial which was initially unveiled on June 16th 2022 is actively recruiting patients. Only 7 people are needed at the single location specified."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger